Victoria Hale of Institute for OneWorld Health Named Fellow by International Women's Forum

September 15, 2003

The Institute for OneWorld Health, the first nonprofit pharmaceutical company in the United States, today announced that CEO Victoria Hale, Ph.D., has been named a Leadership Foundation Fellow for 2003-2004. Hale is one of 14 women selected from a field of more than 50 finalists from all over the world. She is founder and CEO of OneWorld Health, whose experienced team of pharmaceutical scientists uncovers promising drug candidates and advances them through clinical trials and regulatory approval to treat the poorest people in the developing world.

This honor is the third international award in three weeks that recognizes Hale's leadership and vision in establishing OneWorld Health. On Sept. 3 she was named one of five global laureates in health by the Tech Museum of Innovation (San Jose, Calif.). One week prior to that, she was selected as one of 10 outstanding global entrepreneurs by the Schwab Foundation for Social Entrepreneurship in Geneva, Switzerland (http://www.oneworldhealth.org/news/news.html).

The Leadership Foundation is the educational and charitable arm of the International Women's Forum, a global association of about 3,800 top women leaders from 20 countries. The Leadership Foundation Fellows Program is the only leadership training of its kind in the world, designed for women of cultural, professional and geographic diversity. Aimed at high potential women who have the ability to excel at the highest levels of their organizations, the Fellows Program sustains, grooms and promotes up-and-coming women leaders.

Hale's pharmaceutical career spans 15 years, including regulatory and industry experience at the U.S. Food and Drug Administration and biotech pioneer Genentech, Inc. At the FDA, Hale and a team of colleagues led a successful two-year campaign to ensure women and minorities were included in clinical trials, ending an exclusionary practice that persisted into the 1990s. She is an advisor to the World Health Organization for building ethical review capacity in the developing world, and has served as Expert Reviewer to the National Institutes of Health on the topic of biodiversity. She received her Ph.D. from the University of California at San Francisco, where she maintains a faculty position. Under Hale's leadership, the three-year-old company has developed a drug portfolio, ranging from early-stage compounds to a late-stage drug in clinical trials, in four deadly parasitic disease areas: malaria, diarrhea, leishmaniasis, and Chagas. Strategic collaborations with pharmaceutical, biotechnology, university and government organizations have resulted in accelerated drug development and promising new treatments for people in the developing world.

"As a woman in a predominantly male scientific culture and as a social entrepreneur carving out new territory for an enterprise that is also lacking female mentorship, leveraging institutional change requires powerful connections and partnerships," Hale says. "This fellowship is a tremendous opportunity to learn and share skills and insight with women at the vanguard of leadership around the world."
-end-
The Leadership Foundation Program offers Fellows skills training, insight and teaching from internationally acclaimed experts and select members of the International Women's Forum, many of whom are pioneers in breaking barriers of gender, race, and bias. As a Fellow, Hale will participate in a program spread over the next 12 months that includes customized training sessions at Harvard University's John F. Kennedy School of Government and Cambridge University. More information on the International Women's Foundation may be found at http://www.iwforum.org/leadership/

The Institute for OneWorld Health advances global health by developing new, affordable medicines for infectious diseases that disproportionately affect people in the developing world. OneWorld Health accomplishes this through an entrepreneurial business model in which its scientists identify promising drug leads and drive their development from pre-clinical studies to clinical trials through regulatory approval. The Institute for OneWorld Health, headquartered in San Francisco, Calif., is a tax-exempt 501(c) (3), U.S. corporation (http://www.oneworldhealth.org).

Institute for OneWorld Health

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.